FindTrial
Sign In

PD-0325901

DRUG8 trials

Sponsors

Pfizer, Dana-Farber Cancer Institute, The Netherlands Cancer Institute, University of Alabama at Birmingham, Sharp HealthCare

Conditions

Advanced CancerBreast NeoplasmsCarcinoma, Non-Small-Cell LungColonic NeoplasmsColorectal CancerKRAS Mutant Non-Small Cell Lung CancerMelanomaNeurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN

Phase 1

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.
TerminatedNCT00147550
PfizerBreast Neoplasms, Colonic Neoplasms, Melanoma
Start: 2004-02-29End: 2013-07-31Updated: 2013-09-13
Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
TerminatedNCT01347866
PfizerAdvanced Cancer
Start: 2011-10-31End: 2015-12-31Updated: 2018-10-29
PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors
CompletedNCT02022982
Dana-Farber Cancer InstituteKRAS Mutant Non-Small Cell Lung Cancer, Solid Tumors
Start: 2014-01-31End: 2021-06-30Updated: 2024-03-19
Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
CompletedNCT02039336
The Netherlands Cancer InstituteColorectal Cancer
Start: 2014-04-02End: 2018-08-07Updated: 2025-07-08
MEK and MET Inhibition in Colorectal Cancer
CompletedNCT02510001
University of OxfordColorectal Cancer, Solid Tumor
Start: 2014-11-30End: 2018-12-03Updated: 2021-07-13

Phase 2

MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer
TerminatedNCT00174369
PfizerCarcinoma, Non-Small-Cell Lung
Start: 2005-11-30End: 2007-06-30Updated: 2009-03-17
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
CompletedNCT02096471
University of Alabama at BirminghamNeurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
Start: 2014-06-30End: 2018-08-01Updated: 2019-01-10

Unknown Phase

A Single Patient IND for PD-0325901
NCT02297802
Sharp HealthCarePrior Treatment With PD-0325901 With Ongoing Clinical Response
Start: 2013-06-30End: 2013-07-31Updated: 2014-11-26

Related Papers

NFS-18. LOWER BODY SURFACE AREA IS ASSOCIATED WITH INCREASED LIKELIHOOD OF PLEXIFORM NEUROFIBROMA RESPONSE TO MEK INHIBITION
Neuro-Oncology2024-06-18
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer
British Journal of Cancer2020-03-0947 citations
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
2017-12-0178 citations
Abstract 2340: Thymidine kinase activity as a response marker for CDK 4/6 inhibition
Cancer Research2017-07-012 citations
Abstract 3157: Serial droplet digital PCR (ddPCR) of plasma cell-free DNA (cfDNA) as pharmacodynamic (PD) biomarker in Phase 1 clinical trials for patients (pts) with KRAS mutant non-small cell lung cancer (NSCLC)
Cancer Research2016-07-153 citations
Randomized phase Ib/II study of PF-05212384 plus 5-fluorouracil-leucovorin-irinotecan (FOLFIRI) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer (B2151007; NCT01937715).
Journal of Clinical Oncology2014-05-203 citations
Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.
2011-04-2453 citations